Is NRXS or NXL more undervalued in 2026?

CirclFi compares Neuraxis, Inc. (NRXS) and Nexalin Technology, Inc. (NXL) using 13 institutional-grade valuation models. NRXS has a Quality of Company score of 6.9/10 while NXL scores 5.7/10.

Which is a better buy — NRXS or NXL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NRXS and NXL valuations compare?

NRXS at $7.41 and NXL at $0.61 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NRXS vs NXL Valuation Comparison 2026 — Intrinsic Value Analysis

NRXS

Electromedical & Electrotherapeutic Apparatus

Neuraxis, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$7.41

Last close

Models

10/13

Active

NXL

Electromedical & Electrotherapeutic Apparatus

Nexalin Technology, Inc.

Quality

5.7

out of 10

Value Trap

LOW

Price

$0.61

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	NRXS Fair Value	NRXS Upside	NXL Fair Value	NXL Upside
Bayesian DCF	Intrinsic	$2.02	-72.7%	$0.13	-79.2%
Earnings Power Value	Intrinsic	$1.57	-80.6%	$0.05	-86.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NRXS vs NXL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NRXS vs NXL — Which Stock Is More Undervalued?

NRXS scores higher with a 6.9/10 quality rating vs NXL's 5.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Neuraxis, Inc. (NRXS) and Nexalin Technology, Inc. (NXL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NRXS currently trades at $7.41 with a QOC of 6.9/10, while NXL trades at $0.61 with a QOC of 5.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).